Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review by Lakhan, Shaheen E & Vieira, Karen F
RESEARCH Open Access
Nutritional and herbal supplements for anxiety
and anxiety-related disorders: systematic review
Shaheen E Lakhan
*, Karen F Vieira
Abstract
Background: Over the past several decades, complementary and alternative medications have increasingly
become a part of everyday treatment. With the rising cost of prescription medications and their production of
unwanted side effects, patients are exploring herbal and other natural remedies for the management and
treatment of psychological conditions. Psychological disorders are one of the most frequent conditions seen by
clinicians, and often require a long-term regimen of prescription medications. Approximately 6.8 million Americans
suffer from generalized anxiety disorder. Many also suffer from the spectrum of behavioural and physical side
effects that often accompany its treatment. It is not surprising that there is universal interest in finding effective
natural anxiolytic (anti-anxiety) treatments with a lower risk of adverse effects or withdrawal.
Methods: An electronic and manual search was performed through MEDLINE/PubMed and EBSCO. Articles were
not discriminated by date of publication. Available clinical studies published in English that used human
participants and examined the anxiolytic potential of dietary and herbal supplements were included. Data were
extracted and compiled into tables that included the study design, sample population, intervention, control, length
of treatment, outcomes, direction of evidence, and reported adverse events.
Results: A total of 24 studies that investigated five different CAM monotherapies and eight different combination
treatments and involved 2619 participants met the inclusion criteria and were analyzed. There were 21 randomized
controlled trials and three open-label, uncontrolled observational studies. Most studies involved patients who had
been diagnosed with either an anxiety disorder or depression (n = 1786). However, eight studies used healthy
volunteers (n = 877) who had normal levels of anxiety, were undergoing surgery, tested at the upper limit of the
normal range of a trait anxiety scale, had adverse premenstrual symptoms or were peri-menopausal, reported
anxiety and insomnia, or had one month or more of elevated generalized anxiety. Heterogeneity and the small
number of studies for each supplement or combination therapy prevented a formal meta-analysis. Of the
randomized controlled trials reviewed, 71% (15 out of 21) showed a positive direction of evidence. Any reported
side effects were mild to moderate.
Conclusions: Based on the available evidence, it appears that nutritional and herbal supplementation is an
effective method for treating anxiety and anxiety-related conditions without the risk of serious side effects. There is
the possibility that any positive effects seen could be due to a placebo effect, which may have a significant
psychological impact on participants with mental disorders. However, based on this systematic review, strong
evidence exists for the use of herbal supplements containing extracts of passionflower or kava and combinations
of L-lysine and L-arginine as treatments for anxiety symptoms and disorders. Magnesium-containing supplements
and other herbal combinations may hold promise, but more research is needed before these products can be
recommended to patients. St. John’s wort monotherapy has insufficient evidence for use as an effective anxiolytic
treatment.
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Mental disorders plague millions of people around the
world. Depression and anxiety are two of the most com-
mon mental disorders, affecting nearly 55 million people
in the United States alone [1]. The complexities of the
central nervous system make diagnoses, treatment, and
amelioration of these debilitating illnesses exceptionally
difficult. Advancement in these areas would be invalu-
able contributions in the effort to reduce the global
impact of anxiety-based conditions. The universality of
herbal remedies in many cultures makes them an appro-
priate treatment to explore.
According to the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV-TR), anxiety is characterized
by a feeling of persistent worry that hinders an indivi-
dual’s ability to relax [2]. This can range from the tran-
sient anxiety levels a person feels before surgery or a
menstrual cycle to the pervasive feeling of nervousness
that characterizes an anxiety disorder (e.g. generalized
anxiety disorder, obsessive-compulsive disorder, panic
disorder and social phobia). The impact of the anxiety is
not limited to consistent stress, which is associated with
higher risk of cardiovascular and cerebrovascular disease
[3]. Anxiety also has debilitating physical manifestations
as headaches, uncontrolled trembling and sweating,
muscle tension and aches, among others.
To date, the biological explanations for many types of
anxiety disorders remain inadequate. Postulations have
implicated a dysregulation of specific neurotransmitters
such as serotonin, dopamine and gamma-aminobutyric
acid (GABA) as potential causes for both depression and
anxiety disorders [4-6]. These hypotheses are based on the
results of pharmacological treatments, but there are no
definitive clinical trials that demonstrate the dysregulation
of these neurotransmitters as causative factors of anxiety,
potentially explaining why the treatment of anxiety with
antidepressants is often ineffective. Thus far, cognitive
behavioural therapy (CBT) has proven to be the most effec-
tive, long-term treatment for anxiety-related disorders [7].
With the lifetime prevalence of anxiety disorders
reaching 16.6% worldwide [8], great strides have been
made with ongoing research into its causes and treat-
ments. In addition to antidepressants, serotonin-specific
reuptake inhibitors (SSRIs) and benzodiazepines have
also been prescribed to patients suffering from GAD
[9,10]. However, while often effective, both of these
classes of drugs come with many unwanted side effects
such as suicidal ideation, decreased alertness, sexual dys-
function and dependency [11-16]. Additionally, the costs
of these medications pose problems to patients who
must take them on a daily, long-term basis
As a result, there has been increased interest in the
use of complementary and alternative medicines (CAM)
as a natural method for treating numerous types of
anxiety. Herbs such as passionflower, kava, St. John’s
wort and valerian root, as well as the amino acid lysine
and the cation magnesium, have been used for centuries
in folk and traditional medicine to calm the mind and
p o s i t i v e l ye n h a n c em o o d .H o w e v e r ,t h ee f f i c a c ya n d
safety of utilizing CAMs to treat anxiety, both as a
symptom and as a disorder, has only just begun to be
rigorously tested in clinical trials within the last 10 to
15 years [17-19].
A number of reviews of the clinical effectiveness of
herbal and nutrient treatments for depression, anxiety
disorders, and sleep disturbance have been published
over the past decade [19-25]. These have reviewed data
associated with a number of treatments, including St.
John’s Wort, S-adenosyl-methionine (SAM-e), B vita-
mins, inositol, choline, kava, omega-3 fatty acids/fish
extracts, valerian, lavender, melatonin, passionflower,
skullcap, hops, lemon balm, black cohosh, ginkgo biloba,
extracts of Magnolia and Phellondendron bark, gamma-
aminobutyric acid (GABA), theanine, tryptophan and
5-hydroxytryptophan (5-HTP). However, none of these
studies has been conducted in a systematic way.
The objective of this paper is to systematically review
and summarize the available literature on herbal reme-
dies and dietary supplements for treating anxiety and
related symptoms in order to aid mental health practi-
tioners in advising their patients and provide insight for
future research in this field.
Methods
Search strategy
MEDLINE/PubMed and EBSCO databases were searched
without regard for date of publication, using the search
terms “alternative therapies,”“ herbal supplement” and
individual herb and supplement names from popular
sources, each crossed with the term “anxiety.” In addition,
key publications were hand-searched for references. [See
Additional file 1 for a Quality of Reporting of Meta-
analyses (QUOROM) statement checklist.]
Selection criteria
The search was restricted to herbs and supplements
that acted as anxiolytic agents and whose effects were
measured either through quantitative rating scales or
self-reports. Studies also had to be published in Eng-
lish, conducted with human subjects, have a sample
s i z eg r e a t e rt h a n1 0 ,u s eaw h o l ee x t r a c to ft h ep l a n t( i f
applicable) and detail data clearly. Case studies, review
articles, meta-analyses, safety trials and studies that
attempted to link vitamin and mineral deficiencies to
the presence or absence of anxiety symptoms were
excluded, as were trials in animals. Studies of anxiety
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provide supporting evidence.
Data abstraction and synthesis of results
Study results were abstracted into data tables (Tables 1,
2, 3. 4, 5, 6). Because of the heterogeneous nature of the
patients, preparations and outcome measures, data pool-
ing was not possible. Therefore, the data was summarized
qualitatively. The most common outcome measures
encountered in these trials included: Hamilton Anxiety
S c a l e( H A M A ) ,S t a t eT r a i tA n x i e t yI n v e n t o r y( S T A I ) ,
Erlanger Anxiety, Tension and Aggression Scale (EAAS),
Bf-S self-rating scale of well-being, Anxiety Sensitivity
Index (ASI), and Clinical Global Impressions (CGI) scale.
Some studies used measurements of anxiety biomarkers
such as adrenocorticotropic hormone, cortisol, adrenaline,
noradrenaline and chromogranin-A levels; skin conduc-
tance; heart rate; and blood pressure. A significant posi-
tive change in at least one of the primary outcome
measures was required to categorize the trial as positive.
Table 1 Participant characteristics
Passionflower Kava St. John’s wort Lysine Magnesium All studies
Patients (n) 278 1054 762 137 388 2619
Gender
Male 46 (17%) 227 (22%) 246 (32%) 83 (61%) 130 (34%) 732 (28%)
Female 50 (18%) 759 (72%) 516 (68%) 54 (39%) 258 (66%) 1637 (63%)
Not Reported 182 (65%) 68 (6%) - - - 250 (9%)
Age range (years) 19-47 18-75 18-65 20-59 18-82 18-82
Race/Ethnicity
Asian - 2 (< 1%) - 108 (79%) - 110 (4%)
Caucasian - 401 (38%) 83 (11%) 29 (21%) - 513 (20%)
African American - 14 (1%) - - 14 (1%)
Hispanic - 7 (< 1%) - - 7 (< 1%)
Native American - 7 (< 1%) - - 7 (< 1%)
Not Reported 278 (100%) 623 (59%) 679 (89%) 316 (100%) 1896 (72%)
Table 2 Trials testing passionflower
Reference Study
Design
Sample
Population
Intervention Control Length of
Treatment
Outcomes Direction
of
Evidence
Reported Adverse
Events
Bourin (1997)
[34]
Randomized;
Double-
blind;
Parallel
Group
182
outpatients
with
adjustment
disorder with
anxious mood
Euphytose
1;
2 tablets, 3
times a day
Placebo
tablets
28 days Significant reduction
in HAMA scores
(from D7 to D28) in
favour of Euphytose
treatment
+ No serious AEs.
Dry mouth
Headache
Constipation
Drowsiness
Akhondzadeh
(2001) [32]
Randomized;
Double-
blind;
Parallel
group
36
outpatients
with DSM-IV
for GAD for at
least 6
months
45 drops/
day of
Passiflora
extract plus
placebo
tablet
Oxazepam
30 mg/day
plus
placebo
drops
4 weeks Decrease in HAMA
for both
treatments
2; overall
no
significant difference
in efficacy between
treatments
+ Higher impairment of job
performance in
oxazepam group; overall
no significant difference
in total side effects
3
Movafegh
(2008) [33]
Randomized;
Double-
blind;
Parallel
Group
60 patients
undergoing
inguinal
herniorrhaphy
Oral
Passiflora
incarnata
(500 mg,
Passipy™
IranDarouk)
Placebo Given as
pre-
medication
90 minutes
before
surgery
NRS anxiety scores
were significantly
lower in the
passiflora group
+ Not reported
AEs: Adverse events; HAMA: Hamilton Anxiety Scale; DMS-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; GAD: generalized anxiety
disorder; NRS: numerical rating scale.
1. Combination of Crataegus oxyacantha (10 mg), Ballota foetida (10 mg), Passiflora incarnata (40 mg), Valeriana officinalis (50 mg), Cola nitida (15 mg) and
Paullinia cupana (15 mg).
2. D4 oxazepam; D7 passiflora.
3. Passiflora, mild/moderate: Dizziness, Drowsiness, Confusion, Ataxia, Allergic reaction, Impairment of job performance.
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Reference Study
Design
Sample
Population
Intervention Control Length of
Treatment
Outcomes Direction
of
Evidence
Reported
Adverse
Events
Volz
(1997) [42]
Randomized;
Double-blind;
Parallel Group
101 outpatients
with anxiety of
non-psychotic
origin
1
Kava-kava extract WS
1490 (90- 110 mg
dry extract = 70 mg
kl per capsule)
Placebo 24 weeks Significant
reduction in
anxiety (HAMA,
CGI, SCL-90-R,
AMS) in favour of
kava-kava
treatment.
+ Excellent
tolerability,
similar to
placebo; no
clinically
relevant
changes in
laboratory
results.
Stomach upset.
Scherer
(1998)*
[48]
Open-label;
Uncontrolled
Observational
study
52 outpatients
with
nonpsychotic
anxiety
Kava preparation (no
dose reported in
abstract)
N/A Not
reported
in abstract
42 patients
(80.8%) rated
kava treatment as
“very good” or
“good”.
+ Rare
Malsch
(2001) [45]
Randomized;
Double-blind;
Parallel group
40 adult
outpatients with
non-psychotic
nervous anxiety,
tension and
restlessness,
impairing work
performance,
normal social
activities and
relationships
2
Pre-treatment with
benodiazepines
(tapered off over
two weeks) followed
by capsules of
50 mg/day of dry
extract standardized
to 35 mg kava
lactone for three
weeks
Pre-treatment
with
benodiazepines
(tapered off
over two
weeks) followed
by placebo for
three weeks
5 weeks Significant
reduction in
anxiety (HAMA,
Bf-S, EAAS, CGI) in
kava-treated
group.
+ No serious
adverse events
Watkins
(2001) [44]
Randomized;
Double-blind;
Parallel Group
13 patients with
GAD
Kava 280 mg/day
(standardized to 30%
kavalactones)
Placebo 4 weeks Significant
improvement in
baroreflex control
of heart rate in
kava-treated
group;
respiratory sinus
arrhythmia did
not respond to
kava treatment.
+ Not reported
Connor
(2002) [52]
Randomized;
Double-blind;
Parallel Group
38 adults with
DSM-IV GAD
3
Kava (standardized
to 70 mg
kavalactones [kl]).
Treatment initiated
at 149 mg kl/day
and increased to
280 mg kl/day for
the next 3 weeks.
Placebo 4 weeks No significant
difference to
placebo
4
- Well tolerated.
No evidence of
withdrawal or
sexual side
effects.
Boerner
(2003) [43]
Randomized;
Double-blind;
Parallel Group
129 outpatients
diagnosed with
GAD (GAD;
ICD-10: F41.1)
400 mg/day Kava
extract LI 150
(standardized to 30%
kavapyrones,
extraction solvent
96% ethanol in
water, drug-extract
ratio 13-20:1)
(1) 10 mg/day
Buspirone or (2)
100 mg/day
Opipramol
8 weeks Kava was shown
to be as effective
as reference
treatments; 75%
of patients
responded (50%
reduction of
HAMA score).
+ 1 treatment-
related adverse
event.
No systematic
difference
between
treatments.
No liver toxicity
reported
5.
Cagnacci
(2003) [46]
Randomized;
Open;
Parallel
Groups (3)
80 peri-
menopausal
women
Calcium (1 g/day)
plus:
(1) Kava-Kava,100
mg/day (55% of
kavaina; Natural
Bradel, Milano, Italy)
(2) Kava-Kava,
200 mg/day
Calcium
(1 g/day)
3 months Significant
reduction in STAI
scores in favour
of combination
treatment.
+ Mild/moderate:
Nausea
Gastric pain.
No liver
toxicity.
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Gastpar
(2003) [50]
Randomized;
Double-blind;
Parallel Group
141 adult
outpatients
diagnosed with
neurotic anxiety
6
150 mg/day kava
special extract WS
1490 (standardized
to 35 mg kl)
Placebo 4 weeks Pronounced
decrease in ASI
score for the kava
group; however
not statistically
significant overall;
however an
exploratory
analysis of
variance across
the differences
between
treatment end
and baseline,
with center as a
second factor,
showed
superiority of
kava over
placebo.
- Increased
tiredness.
No liver toxicity
Jacobs
(2005) [53]
Randomized;
Double-blind;
Parallel Group
(3)
391 healthy
volunteers with
anxiety
7 and
insomnia
(1) 100 mg kl/day
kava (30% total
kavalactones in
extract) with valerian
placebo
(2) 6.4 mg/day
valerian (1%
valerenic acid in
extract) with kava
placebo
Double placebo 28 days Greater
reductions in
placebo group,
but not
statistically
significant (STAI-
State substest).
- Similar
frequency
between
treatments and
placebo.
No reports of
liver toxicity
Sarris
(2009) [47]
Randomized;
Double-blind;
Crossover
41 adult
participants with
1 month or
more of
elevated
generalized
anxiety
Kava tablets (250
mg/day
kavalactones)
Placebo 3 weeks Highly significant
reduction in
anxiety (HAMA,
BAI, MADRS) in
kava-treated
group.
+ No serious
adverse events.
Mild dizziness,
nausea.
No liver
toxicity.
Sarris
(2009) [51]
Randomized;
Double-blind;
Crossover
28 adults with
MDD and co-
occurring
anxiety
Hypericum
perforatum
8
(1 × 1.8 g tablet,
three times/day);
Kava rhizome
aqueous extract
9
(1 × 2.66 g tablet, 3
times/day)
Placebo 4 weeks Combination
treatment had no
significant effects
on anxiety (BDI-II).
- No serious
adverse events.
Mild
gastrointestinal
upset.
No liver toxicity
HAMA: Hamilton Anxiety Scale; CGI: Clinical Global Impressions; SCL-90-R-ANX: Self-Report Symptom Inventory-90 Items revised, subscore somatic anxiety; AMS:
Adjective Mood Scale; kl: kavalactones (kl); Bf-s: Befindlichkeitsskala [subjective well-being score]; EAAS: Erlanger Anxiety, Tension and Aggression Scale; DSM-IV:
Diagnostic and Statistical Manual of Mental Disorders, fourth edition; GAD: generalized anxiety disorder; BAI: Beck Anxiety Inventory; BDI-II: Beck Depression
Inventory-II; NADRS: Montgomery-Asberg Depression Rating Scale; MDD: major depressive disorder; SARA: Self-Assessment of Resilience and Anxiety; HADS:
Hospital Anxiety and Depression Scale.
* No full text available.
1. DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder and adjustment disorder with anxiety.
2. Diagnosis of agoraphobia (300.22), simple (300.29) or social phobia (300.23), generalized anxiety disorders (300.02) or adaptation disturbances (309.24)
according to DSM-III-R.
3. According to the Results section, “Thirty-eight subjects were randomized, including 31 female (82%) and 32 Caucasian participants (97%)...Three subjects
withdrew their consent following the baseline visit...and did not return for further assessment, leaving 35 subjects in the evaluable sample;” however, the
Abstract states: “Thirty-seven adults with DSM-IV GAD were randomly assigned to...treatment.”
4. Post-hoc analyses: kava was superior in low anxiety (SARA) and placebo was superior in high anxiety (HADS; SARA)
5. Slight increases in transaminase levels to above the upper limit of normal were reported in all three groups.
6. DSM-III-R diagnoses 300.02, 300.22, 300.23, 300.29, or 309.24.
7. Scores of at least 0.5 standard deviations above the mean on STAI-State.
8. Standardized to 990 μg of hypericin, and 1500 μg of flavone glycosides.
9. Standardized to 50 mg of kavalactones.
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Reference Study
Design
Sample Population Intervention Control Length of
Treatment
Outcomes Direction
of
Evidence
Reported
Adverse
Events
Taylor
(2000) [63]
Open-label;
Uncontrolled;
Observational
13 subjects with a
primary DSM-IV
diagnosis of OCD of
at least 12 month
duration
Fixed dose of 900
mg/day of 0.3%
hypericin (a
psychoactive
compound in
Hypericum)
N/A 12 weeks Significant
improvement in Y-
BOCS scores in SJW
group (comparable to
those seen in clinical
trials with SSRIs).
+ Diarrhea
Restless sleep
Volz
(2002) [61]
Randomized;
Double-blind;
Parallel Group
149 outpatients
diagnosed with
somatization
Disorder
2,
undifferentiated
somatoformDisorder
3,
or somatoform
autonomic
Dysfunctions
4
Hypericum extract LI
160
(600 mg/day)
Placebo 6 weeks Significant reduction in
anxiety (HAMA-SOM,
CGI, HAMA-T, HAMA-
PSY, HDS, SCL-90-R,
SCL-90-R-ANX) in
favour of SJW
treatment.
+ Verywell
tolerated.
Mild/moderate:
Abdominal pain
Arthritis
Arrythmia
Bronchitis
Cystitis
Headache
Neuralgia
Muller
(2003) [62]
Open-label;
uncontrolled
observational
500 patients
diagnosed with
depression comorbid
with anxiety
(1) 500 mg valerian
extract
5 and 600 mg/
day St John’s Wort
6
(2) 1,000 mg valerian
extract
7 and 600 mg/
day St John’s wort
6
N/A 6 weeks Significant reduction in
anxiety disorder
symptoms (HAMA) in
both treatment groups.
Higher dosage results
in greater
improvements.
+ Allergy
Bad dreams
Sleep disorders
Dysphoria
Kobak
(2005) [60]
Randomized;
Double-blind;
Parallel Group
40 subjects with GAD St John’s wort
8;
flexible dose (600-
1800 mg/day), mean
dose at week 12 was
1676 mg/day
Placebo 12 weeks No significant
difference to placebo
(LSAS)
- Similar to
placebo.
Mild/moderate:
Gastrointestinal
upset
Dizziness
Insomnia
Fatigue
Kobak
(2005) [59]
Randomized;
Double-blind;
Parallel Group
60 outpatients with
primary diagnosis of
OCD
St John’s wort LI 160
8;
flexible dose (600-
1800 mg/day), mean
dose at week 12 was
1663 mg/day
Placebo 12 weeks No significant
difference to placebo
(Y-BOCS)
- Similar to
placebo
9.
Mild/moderate:
Headache
Gastrointestinal
symptoms
Fatigue
Agitation
Sleep
disturbance
Sarris
(2009) [51]
Randomized;
Double-blind;
Crossover
28 adults with MDD
and co-occurring
anxiety
Hypericum
perforatum
10
(1 × 1.8 g tablet,
three times/day); Kava
rhizome aqueous
extract
11(1 × 2.66 g
tablet, 3 times/day)
Placebo 4 weeks Combination treatment
had no significant
effects on anxiety
(BDI-II).
- No serious
adverse events.
Mild
gastrointestinal
upset.
No liver toxicity
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; Y-BOCS: Yale-Brown Obsessive-Compulsive Scale; OCD: obsessive-compulsive disorder;
GAD: generalized anxiety disorder; SJW: St John’s wort; SCL-90-R-ANX: Self-Report Symptom Inventory-90 Items revised, subscore somatic anxiety; HAMA: Hamilton
Anxiety Scale; ICD-10; International Classification of Diseases; LSAS: Liebowitz Social Anxiety Scale; HAMA-SOM: Hamilton Anxiety Scale, subscore somatic anxiety; CGI:
Clinical Global Impressions; HAMA-PSY: Hamilton Anxiety Scale, subscore psychic anxiety; HAMA-T: Hamilton Anxiety Scale, total score; HDS: Hamilton Depression
Scale; SCL-90-R: Self-Report Symptom Inventory-90 Items revised; PGI-I: Patient Global Impressions of Improvement; CGI-I: Clinical Global Impressions of Improvement;
CGI-S: Clinical Global Impressions of Severity.
1. Clinician observation [case 1], SCL-90-R [case 2]; self-assessment, HAMA [case 3].
2. ICD-10: F45.0.
3. F45.1.
4. F45.3.
5. Euvegal Balance tablet; drug-extract-ratio 3-6:1.
6. Neuroplant tablet; drug-extract-ratio 2.5-5:1.
7. Euvegal Balance tablet.
8. Drug/extract ratio of 3-6:1.
9. Except agitation which was higher with SJW.
10. Standardized to 990 μg of hypericin, and 1500 μg of flavone glycosides.
11. Standardized to 50 mg of kavalactones.
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Flow of included studies
Electronic searches found 106 papers that were potentially
relevant to the present systematic review. Of these, 24 met
the inclusion/exclusion criteria (see Figure 1 for a flow dia-
gram). Of the 82 that did not meet the criteria, 21 were
excluded from the main review because they were not ori-
ginal research (e.g. reviews or meta-analyses) or were case
studies, 14 did not investigate the supplement as a treat-
ment (e.g. safety analysis, pharmacological evaluations,
study of nutritional deficiencies), 32 did not use human
subjects, and 15 were published in a language other than
English. Some of the excluded papers listed as reviews are
cited in the background and discussion sections of this
manuscript. Papers that were mainly discussions of philo-
sophical and ethical issues were not reviewed at all.
Study characteristics
A total of 24 studies were found that met the aforemen-
tioned requirements. These studies examined the effec-
tiveness of five monotherapies (passionflower, lysine,
m a g n e s i u m ,k a v aa n dS tJ o h n ’s wort) and eight combi-
nation treatments (a herbal combination, multivitamin,
L-lysine + L-arginine, magnesium + vitamin B6,h e r b a l
Table 5 Trials testing lysine
Reference Study
Design
Sample
Population
Intervention Control Length of
Treatment
Outcomes Direction
of
Evidence
Reported
Adverse
Events
Jezova
(2005) [67]
Randomized;
Double-blind;
Parallel
Group
29 healthy male
subjects at the
upper limit of the
normal range of a
trait anxiety scale
1
Mixture of L-lysine
and L-arginine (3 g
each/day)
Placebo 10 days AMino acid treatment
enhanced adrenocorticotropic
hormone, cortisol, adrenaline
and noradrenaline levels and
galvanic skin responses during
stress; no effect on heart rate
and blood pressure.
+ None
Smriga
(2007) [68]
Randomized;
Double-blind;
Parallel
Group
108 healthy
Japanese adults
Oral L-lysine (2.64 g/
day) and L-arginine
(2.64 g/day)
Placebo 1 week L-lysine/L-arginine treatment
significantly reduced trait and
state anxiety; also decreased
basal levels of salivary cortisol
and chromogranin-A in male
subjects
+ None
STAI: State Trait Anxiety Inventory.
Table 6 Trials testing magnesium
Reference Study
Design
Sample
Population
Intervention Control Length of
Treatment
Outcomes Direction
of
Evidence
Reported
Adverse Events
Carroll
(2000) [75]
Randomized;
Double-blind;
Parallel
Group
80 healthy males Berocca: oral
multivitamin
1
Placebo 28 days Multivitamin treatment
significantly reduced
anxiety as measured by
GHQ-28, HADS and
PSS.
+ Not reported
De Souza
(2000) [76]
Randomized;
Double-blind;
Crossover (4)
44 women with
adverse
premenstrual
symptoms but
otherwise in
good health
(1) 200 mg Mg, (2)
50 mg vitamin B6,
(3) 200 mg Mg +
50 mg vitamin B6
per day
Placebo One
menstrual
cycle
200 mg/day Mg +
50 mg/day vitamin B6
significantly reduced
anxiety-related
premenstrual
symptoms
+ Participants were
not specifically
asked, but none
were reported
spontaneously
Hanus
(2004) [77]
Randomized;
Double-blind;
Parallel
Group
264 patients with
generalized
anxiety (DSM-III-R)
of mild-to-
moderate
intensity
2
Sympathyl: extracts
of crataegus
oxyacantha and
eschscholtzia
californica plus
magnesium
Placebo 3 months Significant clinical
improvement in
anxiety
3 in favour of
the combination
treatment
+ No serious AEs
related to
treatment
4
GHQ-28: General Health Questionnaire; HADS: Hospital Anxiety and Depression Scale; PSS: Perceived Stress Scale; DMS-II-R: Diagnostic and Statistical Manual of
Mental Disorders, third edition revised; HAMA: Hamilton Anxiety Scale; HAMA-SOM: Hamilton Anxiety Scale, subscore somatic anxiety; HAMA-T: Hamilton Anxiety
Scale, total score (HAMA-T
1. Multivitamin containing vitamin B1 (15 mg), B2 (15 mg), niacin (50 mg), pantothenic acid (23 mg), B6 (10 mg), biotin (150 mcg), folic acid (400 mcg), B12
(10 mcg), C (500 mg), calcium (100 mg), magnesium (100 mg), zinc (10 mg).
2. Total HAMA score between 16 and 28.
3. Measured by HAMA-T and HAMA-SOM and subjective patient-rated anxiety.
Headache, muscular stiffness, insomnia, drowsiness, indifference, anxiety, palpitations, nausea (4), gastralgia, diarrhea, gastric heaviness, dysuria, colic renal pain,
morning sluggishness (3), asthenia.
Lakhan and Vieira Nutrition Journal 2010, 9:42
http://www.nutritionj.com/content/9/1/42
Page 7 of 14combination + magnesium, calcium + kava, St John’s
wort + kava, St John’s wort + valerian). Of these studies,
13 were randomized controlled trials in outpatients with
aD S M - I V - d i a g n o s e dd i s o r d e r ,a n dt h r e ew e r er a n d o -
mized controlled trials in patients with other types of
anxiety (perimenopausal, menstrual, and pre-surgery).
Five trials were done in healthy volunteers, three of
which recruited healthy volunteers with high-normal
anxiety levels. In addition, there were three uncontrolled
observational studies.
Overall, 2619 participants between the ages of 18 and
82 took part in these studies. Twenty-eight percent were
male, 63% were female and 9% did not have their gen-
der reported (Table 1). Ethnicity/race, although an
important demographic factor, was not reported in 72%
of patients. As a result, it is difficult to draw any over-
arching conclusions from the results because these fac-
tors can significantly affect the potential for herbs to
treat anxiety illnesses.
Some cultures have a greater preference for natural
medicine than modern medicine, and therefore will likely
exhibit positive results towards it. Because culture, gen-
der, and age are potential confounding variables, efforts
should be made to control for them in future studies.
This review presents the available evidence for pas-
sionflower, lysine, magnesium, kava and St John’sw o r t ,
either alone or in combination. Methodological details
and results of these trials are summarized in Tables 2, 3,
4, 5, 6. These tables are divided according to the treat-
ment studied and include the reference, study design,
sample population, intervention, control, outcomes,
direction of evidence, and reported adverse events.
Herbal Medicines
Passionflower
Passionflower or Passiflora incarnata Linn.h a sal o n g
history of use as an anxiolytic agent in folklore and
has been used by people all over the world to treat
anxiety [26]. More importantly, several studies invol-
ving the biochemical makeup of passionflower
have been conducted [27-29]. Between the 1970 s and
1990 s, passionflower was listed as an official plant
drug by the pharmacopoeias of America, Britain,
Germany, France, Switzerland, Egypt and India; its
wide use has made it an acceptable treatment for rest-
lessness and nervousness [30].
The anxiolytic effects of passionflower are well docu-
mented in mice [30,31]. However, one of the problems
with herbal supplements is that plant material contains
thousands of phytochemicals, making it challenging to
pinpoint the specific biochemicals responsible for the
anxiolytic properties. In other words, although herbal
remedies often produce positive results, identifying the
active ingredients can be difficult. Therefore, users of
herbal remedies may be consuming ineffective or possi-
bly toxic substances in addition to the active, anxiolytic
ingredients. To date, three human trials have documen-
ted the efficacy of passionflower as a treatment for anxi-
ety-related disorders [32-34].
One double-blind, placebo-controlled study analyzed
the difference in efficacy between oxazepam, a prescrip-
tion benzodiazepine used to treat chronic anxiety symp-
toms, and passionflower in patients (n = 36) who met
the criteria for GAD [32]. The results showed no differ-
ence between the two anxiolytics with regard to the
treatment of GAD, suggesting that passionflower is as
effective as benzodiazepines in eliminating anxiety
symptoms. Subjects from the passionflower group also
reported lower job impairment performance than those
in the benzodiazepine group; however, subjects in the
benzodiazepine group reported a faster onset of symp-
tom relief.
This anxiolytic effect was also seen in two other sub-
sets of patients: those undergoing surgery (n = 60)
who were treated with passionflower monotherapy
[33], and those diagnosed with adjustment disorder
with anxious mood (n = 182) who were treated
with passionflower in combination with crataegus oxy-
acantha, ballota foetida, valeriana officinalis, cola
nitida and paullinia cupana [34].
Mild adverse events were reported in only one study,
including dizziness, drowsiness and confusion [32]. This
Figure 1 Flow diagram of included studies.
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have a role in the treatment of anxiety and warrants
future research.
Kava
Kava is a drink that is prepared from the plant Piper
methysticum. It has been consumed in many cultures
because it is known to relieve anxiety, restlessness and
insomnia for centuries [35,36]. Several studies in animals
have also demonstrated the kava plant’s abilities as an
anxiolytic agent [37,38]. The attractiveness of kava is
that it is anxiolytic but not sedative or mentally impair-
ing, which are typical side effects caused by benzodiaze-
pines [32]. The biochemical mechanism of kava’s
anxiolytic activity has been postulated to occur through
enhanced ligand binding to GABA type A receptors,
blockage of violated-gated sodium channels and calcium
ion channels, norepinephrine and dopamine reuptake
inhibition, and reversible inhibition of monoamine oxi-
dase (MAO) B [see [39] for a review]. To note, the bind-
ing of kava extracts to several neurotransmitters such as
GABAA1, dopamine D2 and the opiates (μ and δ), were
demonstrated in vitro and in the rat brain [40,41].
The first randomized, placebo-controlled, double-blind
study of kava for the treatment of patients who were
diagnosed with anxiety disorder was conducted in 1997
[42]. The subjects (n = 101) were given either an extract
of kava or a placebo for 25 weeks. The participants who
were given the kava extract showed improvement in
their primary and secondary anxiety symptoms based on
the HAMA – a method of patient self-reporting – and a
CGI, which was determined by physicians. Primary anxi-
ety is described as the inability to regulate stress and
anxiety since early childhood. Secondary anxiety, which
develops later in life, can be caused by clinical disorders.
The researchers concluded that when kava is used an
anxiolytic alternative to benzodiazepines or tricyclic
antidepressants, individuals typically suffer from less
side effects.
These results were later supported by five other RCTs
[43-47] and one uncontrolled, observational study [48].
These studies showed kava’s therapeutic potential both
as a monotherapy for patients with anxiety disorder
[48], GAD [43,44,49], elevated generalized anxiety [47]
and those being tapered off of benzodiazepines [45], as
well as in combination with calcium for perimenopausal
women [46].
However, four RCTs showed that kava alone or in
combination with St John’sw o r ti sn om o r ee f f e c t i v e
than placebo in reducing symptoms of anxiety [50-53].
Two of these studies showed no significant difference
between kava treatment and placebo [51,53], while one
found that placebo was actually better at reducing anxi-
ety symptoms in patients with higher baseline anxiety
scores [52]. According to the researchers, this could
have been partly due to the study population. In this
trial, patients were actively looking for alternative treat-
ments for their GAD and were, therefore, highly moti-
vated for kava treatment to produce an effect. This in
turn could have influenced their response to treatment
and led to an increased placebo effect. It is important to
note that the sample size of this study was very small.
The last negative trial [50] was classified on the basis
that it failed to meet its primary endpoint – a significant
r e d u c t i o ni na n x i e t yb a s e do nt h eZ u n gA n x i e t yS c a l e
from memory. However, an exploratory analysis of var-
iance across the differences between treatment end and
baseline, with the treatment center as a second factor,
showed superiority of kava over placebo. According to
the researchers, this variance between centers did not
endanger the validity of their findings; however, it did
reinforce the importance of standardizing ratings across
participating centers in multi-center studies.
All of these trials also revealed that taking doses less
than 400 mg/day does not cause serious side effects.
This is important to note, especially since the U.S.
Food and Drug Administration (FDA) published a con-
sumer advisory warning in 2002 about the potential
for severe liver damage from kava-containing supple-
ments [54]. This potential, yet rare, risk of hepatitis,
cirrhosis and liver failure led nations such as Canada
and the United Kingdom to ban kava supplements.
However, Teschke et al. reported in 2008, that owing
to the fact that kava was considered to be well toler-
ated until 1998 when the first reported cause of hepa-
totoxicity occurred, these rare, but serious side effects
may have occurred due to poor quality kava, as well as
other risk factors such as overdose, prolonged therapy
and co-medication [55].
Of the 435 clinical trial participants taking kava sup-
plements in our review, some at high doses, no liver
issues were reported. Therefore, the current review sup-
ports the conclusion that liver toxicity is indeed a rare
side effect.
St John’s wort
Hypericum perforatum,o rS tJ o h n ’sw o r t( S J W ) ,i s
derived from the flowering tops of a perennial shrub. It
has been used in traditional medicine for centuries to
treat a wide range of disorders and is licensed in Ger-
many to treat anxiety, depression and sleep disorders
[56]. There are numerous hypotheses for its anxiolytic
effects based on the binding affinity of at least 10 differ-
ent extracts, including naphthodianthrones like hyperi-
cins, flavonoids, xanthones, and bioflavonoids, for
adenosine, GABAA,G A B A B and glutamine receptors, as
well as the inhibition of monoamine oxidase-A and -B
activity and synaptosomal uptake of serotonin, dopa-
mine and noradrenaline (norepinephrine) [57]. Of these
active ingredients, hypericin has been studied the most,
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extracts.
SJW is probably most recognized for its use in depres-
sion. A meta-analysis published in 1996, showed that SJW
was more effective than placebo in treating mild to moder-
ate clinical depression [56]. Based on the author’s recom-
mendations, researchers began comparing the efficacy and
safety profile of SJW against other routinely prescribed
antidepressants. One trial conducted in Germany con-
cluded that SJW was as effective as imipramine in treating
mild to moderate depression (n = 324) [58].
Depression has been linked to anxiety, with many
symptoms, panic attacks for example, overlapping
between the two disorders. Little is known about the
specific reasons for the link in the conditions; however,
there may be as high as an 85% overlap with the diag-
noses and many conventional treatment options are pre-
scribed for both disorders. There has been little study of
the effectiveness of SJW in treating anxiety disorders
specifically, with only four RCTs [51,59-61] and two
uncontrolled observational studies [62,63].
These published studies presented contradictory
results. A small 12-week observational study (n = 13) of
patients with OCD showed that SJW caused significant
improvements, with results comparable to those seen in
clinical trials with SSRIs [63]. However, a larger 12-week
RCT (n = 60) showed no significant difference between
patients treated with SJW (at doses higher than the
observational study) or those treated with placebo [59].
Based on previous studies, OCD has one of the lowest
placebo response rates of all of the anxiety disorders
[64]. For this reason, these negative results were prob-
ably due to lack of response to SJW treatment rather
than the high placebo response rates noted in the nega-
tive kava trials [59].
A second set of RCTs investigated the use of SJW com-
bination treatments for depression with co-morbid anxi-
ety. A combination of SJW and valerian was found to
significantly reduce anxiety disorder symptoms; however,
greater reductions were seen with higher doses of valer-
ian (SJW doses remained constant between treatment
groups), suggesting that valerian has more of an effect on
symptoms [62]. A combination of SJW and kava was
shown to have no significant effects on anxiety [51].
Finally, a RCT of 149 patients with depression with
co-morbid anxiety, OCD and somatization disorder
demonstrated that six weeks of treatment with SJW sig-
nificantly reduced anxiety [61]. However, a RCT of 40
patients diagnosed with generalized social anxiety disor-
der found that SJW was no more effective than placebo
in reducing anxiety symptoms [60]. In the discussion of
this study, the researchers stated that a negative trial
was conducted but speculated that minimum severity
levels may be necessary for SJW to be effective in this
patient population [60].
More research needs to be done using SJW in all the
indications presented in this review in order to deter-
mine its effectiveness. However, the results point to a
potential anxiolytic agent with a side effect profile simi-
lar to placebo. All of the side effects reported in the
reviewed trials were mild to moderate and were most
often cases of gastrointestinal upset, dizziness, sleep
disturbances, and headaches.
Nutritional Supplements
Lysine
It has long been postulated that the dysregulation of
neurotransmitters may be a cause for anxiety. These
neurotransmitters include GABA, serotonin, dopamine
and norepinephrine [4-6]. Amino acids such as L-tyro-
sine and L-tryptophan are known precursors for specific
neurotransmitters. Recent studies in animals have iden-
tified two other amino acids, L-lysine and L-arginine
[65,66], which may influence neurotransmitters involved
in stress and anxiety. L-lysine has been shown to act as
a partial serotonin receptor 4 (5-HT4)a n t a g o n i s t ,
decreasing the brain-gut response to stress as well as
decreasing blood cortisol levels [65]. Based on the
results from animal studies, two placebo-controlled
studies were conducted to analyze the effects of
L-lysine-containing supplements in humans [67,68].
The first of these clinical trials was conducted in
healthy male volunteers who were suffering from high-
trait anxiety based on a STAI questionnaire [67].
Results from this study showed that L-lysine and L-
arginine combination supplements improved partici-
pants’ ability to handle induced stress through an
increase in cortisol, while placebo had no reported
improvement of anxiety symptoms. In the discussion,
the researchers attributed the increase in cortisol to a
previous stress hormone regulation deficiency. A pre-
vious report indicated that during moments of induced
stress, an increase in cortisol levels, which is the typi-
cal reaction in healthy persons, does not increase in
people with high-trait anxiety [69]. This dysregulation
of cortisol may lead to augmented feelings of anxious-
ness when stress is induced.
The second RCT recruited 108 healthy Japanese indi-
viduals [68]. After one week of treatment with an oral
L-lysine and L-arginine supplement, basal levels of sali-
vary cortisol decreased in male subjects (n = 54) but
not in females, presumably because these participants
were not selected based on high-trait anxiety. Supple-
mentation also resulted in significant reductions
in state anxiety (a temporary condition characterized
by apprehension, tension and fear about a specific
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anxiety or a tendency to be anxious) in both males and
females.
For the two available RCTs, it seems that the L-lysine +
L-arginine combination effectively reduces anxiety scores
with no reported side effects. Amino acid supplements
may also help in balancing cortisol levels triggered by
stress in both healthy individuals and those with high
trait anxiety. However, more research needs to be con-
ducted on both lysine combinations and monotherapy to
confirm these results.
Magnesium
Magnesium is a positively charged ion, a cation, that is
involved in many important molecular functions in the
body and has been linked to anxiety-related disorders
[70-74]. To date, three human trials have been con-
ducted that test the anti-anxiety effects of increased
magnesium intake in combination therapies [75-77], and
all showed a positive direction of evidence.
In the first study, 28-day treatments with a multivita-
min that contained large amounts of magnesium, zinc
and calcium dramatically decreased psychological dis-
tress (according to the GHQ-28) compared to placebo,
which worsened symptoms [75]. Results from the HADS
also showed a decrease in anxiety for the treatment
group. The effects became more pronounced as the
multivitamin treatment progressed but could not be
linked solely to magnesium supplementation.
A second study published in 2000 looked at the effects
of magnesium and vitamin B6 supplementation on pre-
menstruation-related anxiety [76]. The women were
given 1) magnesium, 2) B6, 3) magnesium + B6, and 4) a
placebo over four menstrual cycles, respectively. The
average magnesium intake for this study was approxi-
mately 300 mg daily. The women were asked to keep a
log of their symptoms and categorize them into six
groups: anxiety, craving, depression, hydration, other,
and total. The results showed that the combination of
magnesium and B6 created a synergistic affect that pro-
vided women with the greatest relief from premenstrual
anxiety. However, magnesium monotherapy was shown
to provide results similar to placebo.
The third clinical study was conducted in 2004 and
investigated the effects of three compounds in combina-
tion, including magnesium, versus placebo in patients
diagnosed with GAD (n = 264) [77]. The researchers
found that both the magnesium-containing supplement
and the placebo drastically decreased anxiety systems
based on HAMA, a personal assessment, and a physi-
cian’s evaluation, hinting at a potential placebo effect for
this treatment. Also, due to the fact that one of the her-
bal extracts contained in the preparation is closely
r e l a t e dt ot h eo p i u mp o p p y ,t h e s ee f f e c t sm a yn o th a v e
been due to the action of the magnesium.
Although the exact mechani s mh a sy e tt ob ed e t e r -
mined, it appears magnesium supplementation is effec-
tive at treating anxiety and anxiety-related disorders
when used in combination with other vitamins, minerals
and herbal extracts. However, more research of magne-
sium monotherapy and its pharmacology is needed to
determine whether magnesium itself possesses anxiolytic
characteristics. Overall, available literature shows that
magnesium-containing supplements are generally well-
tolerated with very few reported side effects.
Conclusions
Anxiety disorders are one of many common psychologi-
cal ailments. Natural remedies have been used for cen-
turies in many cultures to alleviate anxiety and its
symptoms with surprising effectiveness. In Western cul-
tures, however, research that proves the usefulness of
medicinal herbs and natural substances has only begun
to gain momentum over the past few decades. In addi-
tion, the absence of proper guidelines governing the
production and use of vitamins, minerals, amino acids
and herbs for medicinal purposes is also causing the
clinical prescription of these natural treatments to lag
behind in the United States.
Of the RCTs reviewed in this report, 71% (15 out of
21) showed a positive direction of evidence, and any
reported side effects were mild to moderate. Based on
this data, it appears that nutritional and herbal supple-
ments are effective methods for treating anxiety and
anxiety-related conditions without the risk of serious
side effects. However, the effectiveness of each of the
reviewed combinations and monotherapies has not been
substantiated to the same degree.
Passionflower has been studied in three different
RCTs, twice as a monotherapy and once as part of an
herbal combination. All three of these studies showed a
positive benefit for treatment with passionflower, pro-
viding good evidence of its effectiveness as an anxiolytic
agent. However, since each of these studies was con-
ducted in a different patient type, more research is
needed to prove its efficacy in each indication.
Kava is the most researched supplement in this review
with 11 different studies (10 RCTs and one observa-
tional). Of the RCTs of kava monotherapy, 63% (5/8)
showed treatment significantly reduced anxiety symp-
toms in a variety of patient types. This provides good
evidence for the use of kava in patients with GAD, non-
psychotic anxiety and other anxiety-related disorders.
T h ee v i d e n c ef o rS tJ o h n ’s wort was mixed, with 50%
(3/6) of the studies having positive results. However,
the fact that only 1 out of the 4 RCTs had a positive
direction of evidence and that the active treatment in this
trial was a combination of SJW and valerian suggests that
SJW monotherapy should not be recommended to
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related conditions.
For all three of the reviewed herbal supplements, more
research needs to be done to establish the most effective
dosage and to determine whether this varies between
different types of anxiety or anxiety-related disorders.
Furthermore, as 3 of the 4 herbal combinations showed
positive results, future research should focus on deter-
mining whether herbal combinations are similarly or
more effective than monotherapy as well as refining the
type of herbs and dosages contained in combination
supplements.
Combination nutritional supplements containing
lysine or magnesium also appear to hold promise as
treatments for anxiety symptoms and disorders. Both
RCTs of L-lysine and L-arginine combinations demon-
strated positive results, providing good but limited evi-
dence of its usefulness as a treatment for anxiety.
The evidence for magnesium is mixed. Even though
all three RCTs of magnesium-containing supplements
had positive results, magnesium monotherapy was
shown to be no different than placebo [76], raising the
question of whether magnesium provides any anxiolytic
benefits in combination or whether the results were
based on the actions of the other nutrients/herbal
extracts. However, this study was conducted in women
with premenstrual anxiety rather than an anxiety disor-
der. Future research should focus on elucidating magne-
sium’s mode of action in order to determine if it has
anxiolytic properties and provides any synergistic effects
when combined with other natural anxiolytic agents.
Herbal medicines hold an important place in the his-
tory of medicine, as most of our current remedies, and
the majority of those to be discovered in the future, will
contain phytochemicals derived from plants. While
locating the active ingredients in herbal substances is
pivotal to being able to produce effective supplements,
understanding the quantity needed and potency of dif-
ferent ways of extracting and preparing the phytochem-
icals is vital to creating a standard measure of their
effectiveness. In addition, the dangers of overconsump-
tion and interactions with prescription medications and
over-the-counter medications need to be further ana-
lyzed. This understanding of the standards for effective
preparation further minimizes the chance of side effects
from herbal medicines and helps to create an undisputa-
ble body of evidence for their effectiveness.
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